Bladder Cancer - Results from #60

Atezolizumab Monotherapy versus Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130): Final Overall Survival Analysis from a Randomised, Controlled, Phase 3 Study - Beyond the Abstract January 31, 2024

Molecular Characterization of Plasmacytoid Urothelial Carcinoma and the Impact on Treatment Implications - Beyond the Abstract January 19, 2024

A Novel Therapeutic Strategy for Non-Muscle Invasive Bladder Cancer: OncoTherad® Immunotherapy Associated with Platelet-Rich Plasma - Beyond the Abstract January 8, 2024

Persistent Opioid and Benzodiazepine Use after Radical Cystectomy in Enhanced Recovery after Surgery (ERAS) Patients - Beyond the Abstract January 4, 2024

Circulating Tumor DNA Based Minimal Residual Disease Detection and Adjuvant Treatment Decision-Making for Muscle-Invasive Bladder Cancer Guided by Modern Clinical Trials - Beyond the Abstract December 20, 2023

Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Treatment - Beyond the Abstract December 12, 2023

Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?- Beyond the Abstract December 11, 2023

Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis - Beyond the Abstract November 14, 2023

Sequential Chemo-Immunotherapy in Patients with Locally Advanced Urothelial Cancer – a Non-Randomized Phase II Clinical Trial - Beyond the Abstract November 14, 2023

5-Alpha Reductase Inhibitors (5-ARi) with or without Alpha-Blockers (α-B) for Benign Prostatic Hyperplasia Do NOT Lower the Risk of Incident Bladder Cancer: United States Insurance Claims Data - Beyond the Abstract November 1, 2023

Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis - Beyond the Abstract October 12, 2023

Primary Bladder Sarcoma: A Multi-Institutional Experience From the Rare Cancer Network - Beyond the Abstract October 12, 2023

Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following RC: Two Systematic Reviews and Meta-Analyses of Interplay between RC and Renal Function - Beyond the Abstract October 5, 2023

Y Chromosome Loss in Cancer Drives Growth by Evasion of Adaptive Immunity - Beyond the Abstract October 4, 2023

Incidence and Predictors of Deep Incisional and Organ/Space Surgical Site Infection Following Radical Cystectomy - Beyond the Abstract September 22, 2023

Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review - Beyond the Abstract September 6, 2023

Clinical, Molecular, and Immune Correlates of the Immunotherapy Response Score in Patients with Advanced Urothelial Carcinoma Under Atezolizumab Monotherapy: Analysis of the Phase II IMvigor210 Trial - Beyond the Abstract September 6, 2023

A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer - Beyond the Abstract August 29, 2023

Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS) - Beyond the Abstract August 22, 2023

Female Sexual Function Evaluation and Intraoperative Vaginal Reconstruction in Bladder Cancer - Beyond the Abstract August 18, 2023

Page 4 of 25